Search results for "Pancreatic cancer"

showing 10 items of 177 documents

Contribution of germline mutations in the BRCA and PALB2 genes to pancreatic cancer in Italy

2012

Pancreatic adenocarcinoma (PC) is the third most common cancer associated with BRCA mutations. Most notice has been given to BRCA2, while the association between BRCA1 and PC is less widely reported. Recently, PALB2 has been implicated in both PC and breast cancer (BC) susceptibility. We selected 29 Italian PC patients from a case-control study of PC according to their personal and family history of both PC and breast/ovarian cancer (BC/OC) and tested them for presence of germline mutations in BRCA1, BRCA2 and PALB2. We identified no germline mutations or deletions in PALB2, but detected 7 BRCA mutations (4 in BRCA1 and 3 in BRCA2). These findings suggest that PALB2 does not play a major ro…

MaleCancer Researchendocrine system diseasesSettore MED/06 - Oncologia MedicaBRCAGermlineGermline mutationHereditary breast ovarian cancer syndrome (HBOC)skin and connective tissue diseasesGenetics (clinical)Nuclear ProteinOvarian NeoplasmsAged 80 and overGeneticseducation.field_of_studyBRCA1 ProteinPancreatic NeoplasmNuclear ProteinsMiddle Agedfemale genital diseases and pregnancy complicationsPedigreeItalyOncologyAdenocarcinomaFemaleCase-Control StudieFanconi Anemia Complementation Group N ProteinPancreatic cancer susceptibility; BRCA; PALB2; Hereditary breast ovarian cancer syndrome (HBOC); Germline mutationBreast NeoplasmHumanAdultPALB2PopulationBreast NeoplasmsAdenocarcinomaGermline mutationBreast cancerGeneticPancreatic cancerGeneticsmedicineHumansGenetic Predisposition to DiseaseeducationGerm-Line MutationAgedBRCA2 ProteinTumor Suppressor Proteinbusiness.industryTumor Suppressor ProteinsOvarian NeoplasmCancermedicine.diseasePancreatic cancer susceptibilityPancreatic NeoplasmsCase-Control StudiesPALB2businessGene DeletionFamilial Cancer
researchProduct

Management and prognosis of pancreatic cancer over a 30-year period.

2009

BACKGROUND: The aim of this study was to report on changes in the diagnostic assessment, patterns of care and survival over time for pancreatic cancers. METHODS: A total of 2986 cases of pancreatic cancer from the Digestive Cancer Registry of Burgundy (France) over a 30-year period (1976–2005) were considered. Non-conditional logistic regressions were carried out to identify the factors associated with resection for cure and with the use of chemotherapy. A multivariate relative survival analysis was carried out. RESULTS: Diagnostic procedures have changed. Ultrasonography and computed tomography progressively have become the major diagnostic procedures. There was a slight improvement in sta…

MaleCancer Researchmedicine.medical_specialtyMultivariate analysisPancreatic diseasemedicine.medical_treatmentpancreatic cancerGastroenterologysurvivalstage at diagnosisInternal medicinePancreatic cancerClinical StudiesmedicineHumanscancer registryStage (cooking)Diagnostic Techniques and ProceduresAgedNeoplasm StagingAged 80 and overChemotherapyRelative survivalbusiness.industryCancerMiddle Agedmedicine.diseasePrognosisSurgeryCancer registryPancreatic NeoplasmsLogistic ModelsOncologyMultivariate AnalysisFemalebusinessmanagementBritish journal of cancer
researchProduct

Factors influencing survival after resection of pancreatic cancer. A DNA analysis and a histomorphologic study

1994

BACKGROUND The influence of DNA content on prognosis in stomach cancer has been investigated rarely, and the results are controversial. METHOD The prognostic relevance of the DNA content and histomorphologic parameters was evaluated in 41 patients after resection of pancreatic cancer. RESULTS In the univariate analysis, the DNA content, tumor size, lymph node status, tumor stage, nuclear grade, and type of resection had a statistically significant influence on the prognosis. No association was found between the DNA content and the histomorphologic features. Apart from the operative procedure, the DNA content was the strongest indicator of prognosis in the multivariate analysis. CONCLUSIONS …

MaleCancer Researchmedicine.medical_specialtyPathologyPancreatic diseaseMultivariate analysisGastroenterologyPolyploidyPancreatectomyText miningPancreatic cancerInternal medicinemedicineHumansStomach cancerLymph nodeNeoplasm StagingCell NucleusUnivariate analysisbusiness.industryDNA NeoplasmPrognosismedicine.diseaseDiploidyPancreatic NeoplasmsSurvival Ratemedicine.anatomical_structureOncologyLymphatic MetastasisMultivariate AnalysisLymph Node ExcisionFemalePancreasbusinessFollow-Up StudiesCancer
researchProduct

Celiac plexus block for pancreatic cancer pain: Factors influencing pain, symptoms and quality of life

2003

Neurolytic celiac plexus block (NCPB) is claimed to be an effective method of pain control for pancreatic cancer pain. However, the factors that may influence long-term analgesia, adverse effects, and quality of life after performing NCPB have never been determined. In a prospective multicenter study, 22 patients who underwent NCPB were followed until death. Numerous parameters other than pain and symptom intensity were evaluated, including age, gender, initial site of cancer, sites of pain, possible peritoneal involvement, technique, and oncologic interventions. Indices were calculated to determine the opioid consumption ratio (EAS) and the trend of opioid escalation (OEI). NCPB was effect…

MalePalliative caremedicine.medical_treatmentPopulationAnalgesicCeliac plexusPainCeliac PlexusOpioidCancer epidemiologymedicineHumansProspective StudieseducationProspective cohort studyNeurolytic celiac plexus blockGeneral NursingNeurolysisNursing (all)2901 Nursing (miscellaneous)education.field_of_studybusiness.industryNerve BlockMiddle AgedAnalgesics OpioidPancreatic Neoplasmsmedicine.anatomical_structureAnesthesiology and Pain MedicineOpioidAnesthesiaQuality of LifeNerve blockPancreatic cancer painFemaleNeurology (clinical)businessmedicine.drug
researchProduct

Resection of the mesopancreas (RMP): a new surgical classification of a known anatomical space

2007

Abstract Background Prognosis after surgical therapy for pancreatic cancer is poor and has been attributed to early lymph node involvement as well as to a strong tendency of cancer cells to infiltrate into the retropancreatic tissue and to spread along the peripancreatic neural plexuses. The objective of our study was to classify the anatomical-surgical layer of the mesopancreas and to describe the surgical principles relevant for resection of the mesopancreas (RMP). Immunohistochemical investigation of the mesopancreatic-perineural lymphogenic structures was carried out with the purpose of identifying possible routes of metastatic spread. Methods Resection of the mesopancreas (RMP) was per…

MalePathologymedicine.medical_specialtymedicine.medical_treatmentlcsh:Surgerylcsh:RC254-282Sensitivity and SpecificityMesenteric VeinAnatomical spaceMesenteric VeinsPancreatectomyRisk FactorsPancreatic cancermedicineCadaverHumansNeoplasm InvasivenessLymph nodePancreasAgedAged 80 and overbusiness.industryResearchDissectionlcsh:RD1-811lcsh:Neoplasms. Tumors. Oncology. Including cancer and carcinogensmedicine.diseasePancreatic NeoplasmsDissectionmedicine.anatomical_structureLymphatic systemOncologyPancreatectomySurgeryFemalebusinessPancreasWorld Journal of Surgical Oncology
researchProduct

NEPA (netupitant/palonosetron) for the antiemetic prophylaxis of nausea and vomiting induced by chemotherapy (CINV) with Folfirinox and Folfoxiri eve…

2021

OBJECTIVE: The outbreak of coronavirus disease 2019 (COVID-19) has affected the treatment of cancer patients, with particular regard to the management of both chemotherapy and side effects. Chemotherapy-induced nausea and vomiting (CINV) are amongst the most troublesome side effects that impair patients’ adherence to treatments and their quality of life (QoL). NEPA (Akynzeo®), is an oral fixed-dose combination of netupitant [a neurokinin-1 receptor antagonist (NK1RA), 300 mg] and palonosetron [(5-hydroxytryptamine (serotonin or 5HT) type3 receptor antagonist (5HT3RA), 0.5 mg] which has been shown to be effective in preventing CINV. PATIENTS AND METHODS: This prospective study started before…

MalePyridinesVomitingCINVLeucovorinCOVID-19NauseaMiddle AgedIrinotecanColorectal cancerBevacizumabOxaliplatinPalonosetronNetupitantAntineoplastic Combined Chemotherapy ProtocolsAntiemeticsHumansEmetogenic chemotherapyFemaleFluorouracilProspective StudiesColorectal NeoplasmsPandemicsAdvanced pancreatic cancerAgedEuropean review for medical and pharmacological sciences
researchProduct

Folfirinox in elderly patients with pancreatic or colorectal cancer-tolerance and efficacy

2016

AIM To study the tolerance and the efficiency of FOLFIRINOX in elderly patients diagnosed with colorectal or pancreatic cancer. METHODS This retrospective study included elderly patients aged over 70 years of age treated at Georges-Francois Leclerc Center by FOLFIRINOX for histological proved colorectal or pancreatic cancer between January 2009 and January 2015. Chemotheapy regimen consisted of oxaliplatin (85 mg/m(2) in over 120 min) followed by leucovorin (400 mg/m(2) in over 120 min), with the addition, after 30 min of irinotecan (180 mg/m(2) in over 90 min) then 5 fluorouracil (5FU) (400 mg/m(2) administred intravenous bolus), followed by 5FU (2400 mg/m2 intraveinous infusion over 46 h)…

MaleTime FactorsOrganoplatinum CompoundsColorectal cancerFOLFIRINOXLeucovorinPooled AnalysisInternational-SocietyKaplan-Meier EstimateOlder PatientsGastroenterology0302 clinical medicineRisk FactorsAntineoplastic Combined Chemotherapy Protocols030212 general & internal medicineAged 80 and overAge FactorsGastroenterologyCommon Terminology Criteria for Adverse EventsGeneral Medicine3. Good healthOxaliplatinTreatment Outcome030220 oncology & carcinogenesisDisease ProgressionFolfirinoxFemale[ SDV.MHEP.HEG ] Life Sciences [q-bio]/Human health and pathology/Hépatology and GastroenterologyFluorouracilFranceFolfirinox RegimenColorectal Neoplasmsmedicine.drugmedicine.medical_specialtyOxaliplatin FolfirinoxIrinotecanDisease-Free SurvivalDrug Administration Schedule03 medical and health sciencesPancreatic CancerRetrospective StudyInternal medicinePancreatic cancermedicineHumansChemotherapyGeriatric AssessmentAgedRetrospective StudiesColorectal CancerChi-Square DistributionPerformance statusbusiness.industry[SDV.MHEP.HEG]Life Sciences [q-bio]/Human health and pathology/Hépatology and GastroenterologyElderly Patientsmedicine.diseasePhase-Ii Trial1st-Line TreatmentSurgeryPancreatic NeoplasmsIrinotecanRegimenMultivariate AnalysisCamptothecinOpen-LabelFeasibility TreatmentTomography X-Ray Computedbusiness
researchProduct

Germline copy number variation in theYTHDC2gene: does it have a role in finding a novel potential molecular target involved in pancreatic adenocarcin…

2014

Abstract: Objective: The vast majority of pancreatic cancers occurs sporadically. The discovery of frequent variations in germline gene copy number can significantly influence the expression levels of genes that predispose to pancreatic adenocarcinoma. We prospectively investigated whether patients with sporadic pancreatic adenocarcinoma share specific gene copy number variations (CNVs) in their germline DNA. Patients and methods: DNA samples were analyzed from peripheral leukocytes from 72 patients with a diagnosis of sporadic pancreatic adenocarcinoma and from 60 controls using Affymetrix 500K array set. Multiplex ligation-dependent probe amplification (MLPA) assay was performed using a s…

Malecopy number variations germline alteration pancreatic cancer susceptibility YTHDC2 geneDNA Copy Number VariationsSettore MED/06 - Oncologia MedicaClinical BiochemistryAdenocarcinomaBiologyGermlinePancreatic cancerDrug DiscoverymedicineHumansGenetic Predisposition to DiseaseMultiplexProspective StudiesMultiplex ligation-dependent probe amplificationCopy-number variationAlleleGeneGerm-Line MutationAgedAdenosine TriphosphatasesAged 80 and overPharmacologyPharmacology. TherapyDNA HelicasesMiddle Agedmedicine.diseaseMolecular biologyPancreatic NeoplasmsCase-Control StudiesMolecular MedicineAdenocarcinomaFemaleMultiplex Polymerase Chain ReactionRNA HelicasesExpert Opinion on Therapeutic Targets
researchProduct

Chemoradioimmunotherapy with 5-fluorouracil, cisplatin and interferon-α in pancreatic and periampullary cancer: Results of a feasibility study

2008

Abstract Background Recent studies give rise to the hypothesis, that adjuvant chemoradioimmunotherapy with 5-fluorouracil (5-FU), cisplatin and interferon-α (IFN-α) might be a possible new treatment of pancreatic cancer in resected patients. We report the up-to-now experience at our institution. Patients and methods Eleven patients with histological diagnosis of localized carcinoma of the pancreas ( n  = 7) or periampullary ( n  = 4) were prospectively analyzed. Four patients were deemed unresectable because of local invasion of adjacent organs (neoadjuvant setting) and seven patients underwent curative resection (adjuvant setting). Eight patients were classified as T3 carcinomas and three …

Malemedicine.medical_specialtyPancreatic diseasemedicine.medical_treatmentAntineoplastic AgentsRisk AssessmentGastroenterology03 medical and health sciences0302 clinical medicineInternal medicinePancreatic cancermedicinePeriampullary cancerHumansNeoplasm InvasivenessRadiology Nuclear Medicine and imagingSurvival rateNeoplasm Staging030304 developmental biology0303 health sciencesbusiness.industryPatient SelectionRadiotherapy Dosagemedicine.diseaseCombined Modality Therapypeople.cause_of_deathRecombinant Proteins3. Good healthSurgeryPancreatic NeoplasmsSurvival RateRadiation therapyOncology030220 oncology & carcinogenesisConcomitantInterferon Type IFeasibility StudiesFemaleFluorouracilImmunotherapyCisplatinbusinesspeopleChemoradiotherapyProgressive diseaseCancer/Radiothérapie
researchProduct

Surgical treatment of pancreatic cancer

1984

From 1964 to 1982, there were 782 patients treated for carcinoma of the pancreas. In 174 patients pancreaticoduodenal resection was possible (22%). Until 1977 we performed Whipple procedures, while from 1978 to 1982 total pancreatectomy was preferred. Comparing the results of both methods, we did not find any advantages of total pancreatectomy. Operative mortality did not decrease, survival time did not extend, and the higher resection rates (up to 26%) for more advanced tumor stages were accompanied by greater morbidity. With respect to the patients with inoperable cancer of the pancreas, we found over the last 5 years that the rate of those not undergoing surgery has climbed from 8% to 25…

Malemedicine.medical_specialtyPercutaneousDuodenumbusiness.industryExploratory laparotomyMortality ratemedicine.medical_treatmentAnastomosisPrognosismedicine.diseaseSurgeryPancreatic NeoplasmsPancreatectomyCardiothoracic surgeryPancreatic cancermedicineCarcinomaHumansFemaleSurgerybusinessNeoplasm StagingAbdominal surgeryWorld Journal of Surgery
researchProduct